{"id":5366,"date":"2025-05-19T23:59:04","date_gmt":"2025-05-19T22:59:04","guid":{"rendered":"https:\/\/villpress.com\/?p=5366"},"modified":"2025-05-20T00:05:11","modified_gmt":"2025-05-19T23:05:11","slug":"actinium-faces-shareholder-lawsuit-after-major-stock-drop","status":"publish","type":"post","link":"https:\/\/villpress.com\/de\/actinium-faces-shareholder-lawsuit-after-major-stock-drop\/","title":{"rendered":"Actinium Faces Shareholder Lawsuit After Major Stock Drop"},"content":{"rendered":"

New York-based law firm Faruqi & Faruqi, LLP is urging shareholders of Actinium Pharmaceuticals, Inc.<\/strong> (NYSE: ATNM) to come forward if they suffered losses exceeding $75,000 between October 31, 2022, and August 2, 2024<\/strong>. The firm is currently investigating possible securities law violations by the company and its leadership.<\/p>\n\n\n\n

The investigation follows a significant drop in Actinium’s stock price and allegations that the company misled investors regarding the viability of its Iomab-B Biologics License Application (BLA)<\/strong>. A federal securities class action lawsuit has already been filed, and investors must seek lead plaintiff status by May 26, 2025<\/strong>.<\/p>\n\n\n\n

Allegations of Misleading Statements and FDA Concerns<\/strong><\/h3>\n\n\n\n

According to the complaint, Actinium allegedly made false or misleading statements<\/strong> about the success of its Sierra Trial and the likelihood of FDA approval. The lawsuit claims executives failed to disclose that the Sierra Trial data<\/strong> were unlikely to meet FDA expectations and that follow-up analyses aimed at improving the overall survival narrative were insufficient.<\/p>\n\n\n\n

Additionally, it is believed the company knew the FDA would likely reject or refuse to review<\/strong> the BLA in its current form. This resulted in investor decisions based on overly optimistic and potentially deceptive claims.<\/p>\n\n\n\n

Stock Plummets After Regulatory News Breaks<\/strong><\/h3>\n\n\n\n

The situation escalated on August 5, 2024<\/strong>, when Actinium publicly revealed it would need to conduct another clinical trial<\/strong> to support its BLA filing. Following this announcement, the company\u2019s stock price crashed nearly 60%<\/strong>, dropping from $6.17 to $2.48 on unusually heavy trading volume. This drastic drop caused substantial financial damage to shareholders.<\/p>\n\n\n\n

Legal Options and Shareholder Rights<\/strong><\/h3>\n\n\n\n

Faruqi & Faruqi Partner James (Josh) Wilson<\/strong> is inviting affected investors to call him directly at 877-247-4292<\/strong> or 212-983-9330 (Ext. 1310)<\/strong> for a free consultation on their rights. Investors can also learn more about the case at www.faruqilaw.com\/ATNM<\/a><\/strong>.<\/p>\n\n\n\n

The court will appoint a lead plaintiff\u2014typically the investor with the largest financial loss<\/strong>\u2014to guide the lawsuit on behalf of all others in the class. However, any investor can choose to be involved or opt to remain a passive member of the class.<\/p>\n\n\n\n

Whistleblowers and Former Employees Encouraged to Step Forward<\/strong><\/h3>\n\n\n\n

The firm is also calling on anyone with inside information\u2014including former employees, whistleblowers, and other stakeholders\u2014to come forward. All communications will be kept confidential.<\/p>\n\n\n\n

Faruqi & Faruqi<\/a> has a long-standing reputation in securities litigation, having recovered hundreds of millions of dollars<\/strong> for investors since 1995. They maintain offices in New York, Pennsylvania, California, and Georgia<\/strong>.<\/p>","protected":false},"excerpt":{"rendered":"

New York-based law firm Faruqi & Faruqi, LLP is urging shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) to come forward if they suffered losses exceeding $75,000 between October 31, 2022, and August 2, 2024. The firm is currently investigating possible securities law violations by the company and its leadership. The investigation follows a significant drop […]<\/p>\n","protected":false},"author":1,"featured_media":5367,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"footnotes":""},"categories":[213],"tags":[344],"ppma_author":[331],"class_list":{"0":"post-5366","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-market-news","8":"tag-actinium"},"authors":[{"term_id":331,"user_id":1,"is_guest":0,"slug":"pastakutmanwen","display_name":"Villpress Insider","avatar_url":{"url":"https:\/\/villpress.com\/wp-content\/uploads\/2025\/05\/Logo.png","url2x":"https:\/\/villpress.com\/wp-content\/uploads\/2025\/05\/Logo.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/posts\/5366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/comments?post=5366"}],"version-history":[{"count":1,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/posts\/5366\/revisions"}],"predecessor-version":[{"id":5368,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/posts\/5366\/revisions\/5368"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/media\/5367"}],"wp:attachment":[{"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/media?parent=5366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/categories?post=5366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/tags?post=5366"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/ppma_author?post=5366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}